NSE · SHUKRAPHAR
Shukra Pharmaceuticals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹24 Cr with net profit ₹15 Cr — a 63.9% net margin, versus -27.46% the period before.
Shareholding
As of 2026-09-30
- Promoter51.15%
- Public48.2%
- FII0.44%
- DII0.22%
35,007 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.88× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #11 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,72,094 Cr | 77.13 | 20.27 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹46,645 Cr | 40.71 | 4.5 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹41,035 Cr | 36.16 | 9.06 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹23,578 Cr | 81.82 | 18.3 | 19.14% | 14.89% |
| Shilpa Medicare Ltd. | ₹16,904 Cr | 59.44 | 6.51 | 9.39% | 17.67% |
| Caplin Point Laboratories Ltd. | ₹16,890 Cr | 25.39 | 5.01 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹15,199 Cr | 23.14 | 3.9 | 15.87% | 20.04% |
| Marksans Pharma Limited | ₹13,001 Cr | 25.17 | 4.3 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹6,631 Cr | 48.17 | 5.6 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹5,597 Cr | 44.29 | 5.99 | 12.36% | 18.59% |
| Shukra Pharmaceuticals Limited(this company) | ₹2,853 Cr | 83.71 | 28.31 | 24.55% | 45.4% |
AI analysis
AI-generated · google/gemini-2.5-flashShukra Pharmaceuticals Limited has a market capitalization of Rs 1382 Cr. The company reported a profit margin of 38.88% and a Return on Equity (ROE) of 24.55%. The debt-to-equity ratio is 0.06. As of June 30, 2026, promoter holding stands at 50.9582%.
Positives
- +The company has a high profit margin of 38.88%.
- +Return on Equity is 24.55%.
- +Return on Capital Employed is 31.4961%.
- +Debt-to-equity ratio is low at 0.06.
- +Promoter holding of 50.9582% is above 50% as of June 30, 2026.
Negatives
- −The quarterly net profit declined from 20.36 Cr in December 2025 to -1.72 Cr in March 2026.
- −The quarterly revenue decreased from 39.13 Cr in December 2025 to 6.32 Cr in March 2026.
- −The annual net profit decreased from 5.39 Cr in March 2025 to -1.73 Cr in March 2026.
- −No quarterly results have been disclosed since March 2026.
Financial Performance
The company's quarterly revenue was Rs 6.32 Cr in March 2026, a decrease from Rs 39.13 Cr in December 2025. Net profit for March 2026 was -1.72 Cr, down from 20.36 Cr in December 2025. Annual net profit was 5.39 Cr in March 2025, decreasing to -1.73 Cr in March 2026.
Profitability & Returns
Shukra Pharmaceuticals Limited has a profit margin of 38.88%. The Return on Equity (ROE) is 24.55% and Return on Capital Employed (ROCE) is 31.4961%. Earnings per share (EPS) is 0.5.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.06. The book value per share is 2.05. The annual net profit for March 2026 was -1.73 Cr, with EBITDA at 0.63 Cr for the same period.
Ownership & Pledges
Public shareholding is 48.9242%. There are no promoter shares pledged.
Data as of — price: 2026-10-26 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Shukra Pharmaceuticals Limitedshare price & fundamentals